Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s), details of which are enclosed. Sanofi India Ltd - 500674 - Closure of Trading Window
Pursuant to the Company's Code of Conduct to Regulate, Monitor and Report Insider Trading by Designated Persons we would like to inform you that, inter alia, for the purpose of declaration of financial results of the Company, for the quarter and half year ending 30th June 2022, the trading window of the Company shall remain closed from 1st July 2022 till 48 hours after the announcement of the results to the stock exchanges
Sanofi says COVID-19 vaccine candidate yields positive trial data
"Sanofi-GSK's vaccine is the first candidate to demonstrate efficacy in a placebo-controlled trial in an environment of high Omicron variant circulation," the firm, which is developing the vaccine jointly with Britain's GSK, said in a statement. Sanofi India Ltd - 500674 - Disclosure of Voting results of Postal Ballot (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Sanofi India Ltd has informed BSE regarding the details of Voting results of Postal Ballot, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has approved issue of duplicate share certificates requests in lieu of the original share certificates reported lost/misplaced, details of which are enclosed. Sanofi India Ltd - 500674 - Results Of Postal Ballot
Please find enclosed: 1. Voting results pursuant to Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, signed by the Chairman. 2. Report of Scrutinizer dated 23rd June 2022. The Members of the Company have approved the Ordinary Resolution as embodied in the Postal Ballot Notice dated 26th April 2022, for appointment of Mr. Rodolfo Hrosz as Additional Director and Managing Director of the Company with a majority of votes.
Sanofi, GSK say Covid booster shot works better against Omicron variant
The companies point to the risk of new variants and waning immunity that could lead to an increase in demand for additional booster shots in some populations. Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s), details of which are enclosed: Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has approved issue of duplicate share certificates requests in lieu of the original share certificates reported lost/misplaced, details of which are enclosed.
Pharma major Sanofi India appoints Preeti Futnani as General Manager, Vaccines
Futnani has over two decades of experience in growth and transformation that spans several therapeutic areas and functions within healthcare and finance.